With the bidding for the generics business of Merck set to begin from Monday, domestic pharmaceutical companies in the fray, Ranbaxy Laboratories and Dr Reddy's Laboratories, are unlikely to go for an all-out bidding war.
The decision has come in the wake of allegations of plagiarism against the Mashelkar panel report.
"The product technology is coming from DNDi. Cipla will manufacture and make the product available in southeast Asia and other parts of the world at affordable pre-agreed prices," Amar Lulla, joint managing director, Cipla, said.
The international health organisations, protesting against Swiss pharmaceutical major Novartis AG's legal challenge to provisions of the Indian Patent Act
Even as the domestic pharmaceutical industry is exploring new markets in Latin America and the Commonwealth of Independent States, exports to countries in Africa are declining.
Having cut eight deals last year, the $1.3 billion pharma major Ranbaxy probably has the sharpest negotiating skills in the business.
Ministry to amend Act to bring all oral, skin and hair care products under its purview.
Ranbaxy Laboratories, the biggest member of the Indian Pharmaceutical Alliance, has come out in the open against the alliance's stand on patent issues.
The Mashelkar panel's recommendation to consider all modifications and variants of new chemical entities (NCEs) as patentable has invited criticism from sections of Indian pharmaceutical industry and public interest organisations
The domestic pharmaceutical industry and non-government organisations are up in arms against the first ever Indo-US tie-up on intellectual property rights
Under the banner of the CII, domestic drug majors have approached Cabinet Secretary BK Chaturvedi for being allowed to present their views on the new pharmaceutical policy, scheduled to be discussed by the Union Cabinet on Thursday.
The corporate healthcare segment may replicate the success of the Indian IT sector, say experts.
Panacea Biotec is planning to launch its organ transplantation drugs to Latin American and South East Asian markets.
Dabur Pharma, a leading player in the domestic oncology segment, is busy finalising its marketing strategies for EU, the US and Australia.
The new pharma policy proposed by Chemicals Minister Ram Vilas Paswan is likely to call for a central mechanism to oversee research and development projects in the country.
It aims at slashing the average market prices from 10 to 30 per cent for low-end brands and from 30 to 60 per cent for high-end ones.
Apart from Roche's hepatitis medicine Pegasys, which received a patent in March 2005, there have been no major announcements on grant of product patents.
Pharma Link, a joint venture of leading pharmaceutical support service provider Interpharma Asia-Pacific
Eli Lily, Sanofi Aventis, Bristol Myers approach chemicals ministry.
Pharma companies' hope to have several of their house hold remedy brands like Crocin made available through grocery shops across the country may not materialise.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances